WallStSmart

Carlsmed, Inc. Common Stock (CARL)vsR1 RCM Inc (RCM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

R1 RCM Inc generates 4265% more annual revenue ($2.46B vs $56.44M). RCM leads profitability with a -2.5% profit margin vs -57.8%. RCM earns a higher WallStSmart Score of 39/100 (F).

CARL

Avoid

29

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 8.5
Piotroski: 6/9Altman Z: 1.51

RCM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 5.7Quality: 6.0
Piotroski: 6/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CARL.

RCMUndervalued (+27.7%)

Margin of Safety

+27.7%

Fair Value

$19.79

Current Price

$14.31

$5.48 discount

UndervaluedFair: $19.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CARL2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
58.2%10/10

Revenue surging 58.2% year-over-year

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

RCM1 strengths · Avg: 8.0/10
Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Areas to Watch

CARL4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Altman Z-ScoreHealth
1.514/10

Distress zone — elevated risk

Market CapQuality
$277.29M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-36.0%2/10

ROE of -36.0% — below average capital efficiency

RCM4 concerns · Avg: 2.8/10
PEG RatioValuation
2.064/10

Expensive relative to growth rate

Operating MarginProfitability
3.8%3/10

Operating margin of 3.8%

Return on EquityProfitability
-2.2%2/10

ROE of -2.2% — below average capital efficiency

EPS GrowthGrowth
-99.3%2/10

Earnings declined 99.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : CARL

The strongest argument for CARL centers on Revenue Growth, Debt/Equity. Revenue growth of 58.2% demonstrates continued momentum.

Bull Case : RCM

The strongest argument for RCM centers on Price/Book. Revenue growth of 14.7% demonstrates continued momentum.

Bear Case : CARL

The primary concerns for CARL are EPS Growth, Altman Z-Score, Market Cap.

Bear Case : RCM

The primary concerns for RCM are PEG Ratio, Operating Margin, Return on Equity.

Key Dynamics to Monitor

CARL profiles as a hypergrowth stock while RCM is a turnaround play — different risk/reward profiles.

CARL is growing revenue faster at 58.2% — sustainability is the question.

RCM generates stronger free cash flow (60M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RCM scores higher overall (39/100 vs 29/100) and 14.7% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Carlsmed, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Carlsmed, Inc. develops and operates a surgical platform for the treatment of complex adult spinal deformities that enables surgeons to harness clinical intelligence, advanced image recognition, and 3D printing technologies. The company is headquartered in Carlsbad, California.

R1 RCM Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

R1 RCM Inc (RCM) is a leading provider of technology-driven revenue cycle management solutions that significantly enhance the financial performance of healthcare organizations across the United States. By leveraging advanced analytics and deep industry expertise, R1 RCM offers comprehensive services that optimize billing processes and improve operational efficiency for hospitals and outpatient facilities alike. The company’s innovative approach not only enhances revenue capture but also elevates patient experiences, establishing R1 RCM as a critical player in the evolving healthcare sector. With a strong emphasis on expanding its service offerings and increasing market share, R1 RCM is strategically positioned to capitalize on the growing demand for sophisticated revenue cycle management services.

Want to dig deeper into these stocks?